All companies
Visit website
Eliaz Therapeutics
OperatingEliaz Therapeutics Inc.
Healthcare · Founded 2015
Join the fight against sepsis with our life-saving medical device: XGal-3
Post-money valuation ⓘ
$60.1M
As of May 2026 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price
Total raised
$3,021,837
Across 3 rounds since 2024
Latest share price
$5.56
Reg CF Offering (2026) offering price
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its source$0
$33K
2022
$0
−$548K
2023
$302K
−$955K
2024
$332K
−$1.7M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$302,481
$332,235
Cost of goods sold
$0
$0
$0
$0
Gross margin
—
—
100%
100%
Net income
$33,366
-$548,405
-$954,869
-$1,745,041
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$47,178
$4,886
$32,814
$1,799,510
Accounts receivable
$0
$0
$0
$0
Total assets
$1,052,853
$803,385
$738,015
$2,589,276
Short-term debt
$1,519,988
$1,566,203
$2,346,085
$1,796,731
Long-term debt
$3,255,587
$3,782,811
$3,888,186
$8,033,117
Total liabilities
$4,775,575
$5,349,014
$6,234,271
$9,829,848
Other
Headcount
—
1
5
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$49.5M
Valuation cap
$60.1M
post-money
ELIAZ THERAPEUTICS Future Equity SAFE 1
Reg CF Offering (2025)
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $470.1K / $2.5MInvestors 338Post-money $60.1M
Reg CF annual-report compliance
Delinquent
Filed 1 of 2 annual reports (FY2024–FY2025)
Missing: 2024
338 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 15 filings on EDGARSource: ManualCIK 0002042609Share price $5.56
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.